CORONA Remedies profit and loss

Latest FY26

Revenue: ₹1,403cr
EBITDA: ₹293cr
Net profit: ₹185cr
EPS: ₹30.27

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026

Expenses
	1,559	1,403
	12.0	10.7
	1,571	1,414
	120	104
	213	150
	−48.6	7.1
	449	403
	8.5	7.0
	48.0	37.9
	491	446
	1,281	1,155
	334	293
	286	256
Profit
	290	259
	−18.8	−18.8
	271	240
	58.1	51.5
	5.9	3.8
	64.0	55.3
	0.1	0.0
	207	185
	207	185
	−0.4	0.1
	207	185
	207	185
Per share
	₹33.85	₹30.27
	₹33.85	₹30.27
Revenue detail — as filed
	—	−0.3
Other comprehensive income — detail
	−0.4	0.1
	0.4	−0.1
	59.9	0.1
Per share — as-filed variants
	₹33.85	₹30.27
	₹33.85	₹30.27
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,275	1,142
	81.7%	81.4%
Adjusted (ex-exceptional items) — derived
	290	259
	−18.8	−18.8
	221	200
	₹36.20	₹32.64

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CORONA₹2,050.00

CORONA Remedies Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersERIS MANKIND APLLTD ALIVUS AKUMS AGARWALEYE HCG ADVENZYMESMcap ₹12,538 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,403.2	1,559.1
Other Income	10.7	12.0
Total Income	1,413.8	1,571.1
Expenses
+ Cost of Materials Consumed	103.5	120.2
+ Purchases of Stock-in-Trade	150.4	212.9
+ Changes in Inventories	7.1	-48.6
+ Employee Benefit Expense	403.0	448.9
+ Finance Costs	7.0	8.5
+ Depreciation & Amortisation	37.9	48.0
+ Other Expenses	445.8	491.4
Total Expenses	1,154.6	1,281.4
EBITDA	293.4	334.3
EBIT	255.6	286.2
Profit
PBT before Exceptional Items	259.3	289.7
+ Exceptional Items	-18.8	-18.8
Pretax Income	240.4	270.9
+ Current Tax	51.5	58.1
+ Deferred Tax	3.8	5.9
Tax Expense	55.3	64.0
+ Share of Associates & JVs	0.0	0.1
Net Income	185.1	207.0
+ Net Income — Continuing Ops	185.1	206.9
+ Other Comprehensive Income	0.1	-0.4
Total Comprehensive Income	185.2	206.6
Net Income to Common	185.1	207.0
Per Share
Basic EPS	30.27	33.85
Diluted EPS	30.27	33.85
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	-0.3	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.1	-0.4
+ Tax on Items NOT to be Reclassified	-0.1	0.4
Comprehensive Income — Owners of Parent	0.1	59.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	30.27	33.85
Diluted EPS — Continuing Operations	30.27	33.85
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,142.2	1,274.6
Gross Margin %	81.40	81.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	259.3	289.7
− Exceptional Items (reconciliation)	-18.8	-18.8
Net Income Adj (tax-effected)	199.6	221.4
EPS Adj	32.64	36.20
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00
Paid Up Equity Capital	61.2	61.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.